The clinical outcomes of DM/non-DM, CKD/non-CKD, HF/non-HF groups who received highly selective SGLT2 inhibitors versus less selective SGLT2 inhibitors are demonstrated in Fig. 3D, E and F. The gene discussed is SLC5A2; the disease is chronic kidney disease.